Apollomics Announces Updated Strategic Focus and Leadership Team Changes


Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Originally posted here:
Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Related Posts